A BUDGET IMPACT ANALYSIS OF FIDAXOMICIN VERSUS VANCOMYCIN AND METRONIDAZOLE FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE

被引：0
|
作者：
Leinwand, B. [1 ]
机构：
[1] Avalere Hlth LLC, Washington, DC USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1426
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI7
引用
收藏
页码：A632 / A633
页数：2
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States
    Stranges, Paul M.
    Hutton, David W.
    Collins, Curtis D.
    VALUE IN HEALTH, 2013, 16 (02) : 297 - 304
  • [22] Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea
    Bishara, Jihad
    Wattad, Morad
    Paul, Mical
    CLINICAL INFECTIOUS DISEASES, 2007, 45 (12) : 1646 - 1647
  • [23] Treatment of Metronidazole-Refractory Clostridium difficile Enteritis with Vancomycin
    Follmar, Keith E.
    Condron, Sara A.
    Turner, Immanuel I.
    Nathan, Jaimie D.
    Ludwig, Kirk A.
    SURGICAL INFECTIONS, 2008, 9 (02) : 195 - 200
  • [24] CLOSTRIDIUM-DIFFICILE COLITIS FOLLOWING TREATMENT WITH METRONIDAZOLE AND VANCOMYCIN
    BINGLEY, PJ
    HARDING, GM
    POSTGRADUATE MEDICAL JOURNAL, 1987, 63 (745) : 993 - 994
  • [25] Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
    Crook, Derrick W.
    Walker, A. Sarah
    Kean, Yin
    Weiss, Karl
    Cornely, Oliver A.
    Miller, Mark A.
    Esposito, Roberto
    Louie, Thomas J.
    Stoesser, Nicole E.
    Young, Bernadette C.
    Angus, Brian J.
    Gorbach, Sherwood L.
    Peto, Timothy E. A.
    CLINICAL INFECTIOUS DISEASES, 2012, 55 : S93 - S103
  • [26] A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF FIDAXOMICIN FOR TREATING CLOSTRIDIUM DIFFICILE PATIENTS IN GERMANY
    Watt, M.
    McCrea, C.
    Johal, S.
    Posnett, J.
    Nazir, J.
    VALUE IN HEALTH, 2015, 18 (03) : A233 - A233
  • [27] Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile
    Turner, Nicholas A.
    Warren, Bobby G.
    Gergen-Teague, Maria F.
    Addison, Rachel M.
    Addison, Bechtler
    Rutala, William A.
    Weber, David J.
    Sexton, Daniel J.
    Anderson, Deverick J.
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (04) : 648 - 656
  • [28] Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada
    Wagner, Monika
    Lavoie, Louis
    Goetghebeur, Mireille
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2014, 25 (02): : 87 - 94
  • [29] Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure
    Chilton, C. H.
    Crowther, G. S.
    Freeman, J.
    Todhunter, S. L.
    Nicholson, S.
    Longshaw, C. M.
    Wilcox, M. H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (02) : 451 - 462
  • [30] Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study
    Gentry, C. A.
    Nguyen, P. K.
    Thind, S.
    Kurdgelashvili, G.
    Skrepnek, G. H.
    Williams, R. J., II
    CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (08) : 987 - 993
12345